Device and method for predicting ability to implant in uterus and estimating delivery timing
Bioelectrical impedance measurement in the uterine or vaginal cavity addresses the insufficiencies in existing methods for predicting uterine implantation potential and estimating delivery time, enhancing infertility treatment efficiency and reducing burdens on couples and healthcare systems.
Patent Information
- Application Number
- PCT/JP2024/019026
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for predicting uterine implantation potential and estimating delivery time are insufficient, leading to low success rates in infertility treatments and increased financial, mental, and physical burdens on couples, with no established diagnostic method for implantation failure.
A device and method using bioelectrical impedance measurement in the uterine or vaginal cavity to predict implantation potential and estimate delivery time by comparing measured impedance values to threshold or control values, allowing for prospective evaluation of uterine implantation capacity and timely intervention.
This approach enables efficient infertility treatment by reducing unnecessary embryo transfers, lowering treatment costs, and improving pregnancy rates, while also predicting premature birth, thereby reducing the burden on individuals and potentially addressing declining birth rates.
Smart Images

Figure JP2024019026_28112024_PF_FP_ABST
Abstract
Description
Apparatus and method for predicting uterine implantation capacity and estimating delivery time
[0001] The present invention relates to an apparatus and method for predicting the maternal receptivity for implanting a fertilized egg in the uterus (uterine implantation capacity), and an apparatus and method for estimating the time of delivery.
[0002] Human infertility is defined as the failure to conceive after one year of unprotected sexual intercourse. It is said that currently, 10-15% of all couples of reproductive age suffer from infertility. In recent years, infertility is thought to be on the rise due to factors such as the trend toward later marriage and later childbirth as a result of women's advancement in society, as well as the spread of sexually transmitted diseases.
[0003] Causes of female infertility include those with problems in the ovaries (ovulation), those with problems in the fallopian tubes (egg transport), and those of unknown cause. It is believed that many cases of infertility of unknown cause are due to implantation failure. "Implantation" here refers to the process in which a fertilized egg (embryo) adheres to and invades the uterine lining, and medically, pregnancy is defined as having been established at this point. If there is some problem with the receptive endometrium during this implantation process, resulting in failure to implant, this is called "implantation failure." In other words, "implantation failure" refers to a condition in which fertilization is established and the embryo develops normally, but moves to the uterine cavity, but implantation does not occur normally.
[0004] Based on the concept that human implantation is controlled by three factors: the hormonal environment, endometrial function, and morphology, several methods have been used to assess the fetal development: (1) monitoring blood progesterone levels, (2) measuring endometrial thickness using an ultrasound diagnostic device, and (3) sampling and histological examination of endometrial tissue. Method (3) is not routinely performed in clinical practice due to its high invasiveness and lack of prospective evaluation, despite the fact that endometrial receptivity changes with each menstrual cycle. Methods (1) and (2) are still routinely performed in clinical settings. However, methods (1) and (2) have been reported to be insufficient for prospectively assessing uterine receptivity. Furthermore, these methods often result in failure to conceive despite routinely normal parameters.
[0005] In vitro fertilization and embryo transfer (IVF) has long been a common option in infertility treatment, but the pregnancy rate is approximately 20-30% worldwide, although this rate varies significantly depending on maternal age, making it difficult to consider the treatment efficient. The process leading to conception can be broadly divided into (i) ovulation, (ii) fertilization, and (iii) implantation. However, while current infertility treatments offer diagnostic and treatment methods for problems with (i) and (ii), there are currently no diagnostic methods for (iii). Furthermore, in IVF and embryo transfer, 83%-89% of embryos successfully develop outside the body, yet do not result in pregnancy. While one-third of these cases are thought to be due to problems with the embryo itself, the remaining two-thirds are thought to be due to problems with the recipient uterus, known as implantation failure. For these reasons, diagnosis and treatment of implantation failure are required in current infertility treatments. The low success rate of IVF often places excessive financial, mental, and physical burdens on couples suffering from infertility. Considering perinatal outcomes, it is important for couples who wish to have children to conceive as soon as possible, and for this reason, efficient infertility treatments are desirable. In other words, by prospectively evaluating the uterine implantation capacity for each menstrual cycle, it is possible to provide treatments that are appropriate for that menstrual cycle and are efficient, thereby reducing the physical, psychological, and economic burden on patients.
[0006] Thus, although diagnosis and treatment of implantation failure are required in current infertility treatments, there is currently no practical method for prospectively evaluating the implantation capacity of the uterus, and no established diagnostic method for implantation failure has been established.
[0007] In contrast, because vaginal mucosal impedance in rats is high during proestrus when not pregnant, this impedance has been used as a parameter indicating the breeding period (Non-Patent Document 1). It has also been reported that vaginal mucosal impedance in mice is high during estrus (Non-Patent Documents 2 and 3). However, there have been no attempts to use this parameter to evaluate the implantation capacity of the uterus.
[0008] Therefore, the inventors conducted extensive experiments using a mouse model of human implantation failure, and from the results, developed a method and device for measuring the implantation ability of a subject's endometrium using at least one of the potential difference (e.g., oxidation-reduction potential (ORP)) in the uterine cavity, local impedance in the uterine cavity, and vaginal mucosal impedance as an index (Patent Document 1).
[0009] International Publication No. WO2012 / 070569
[0010] Aplin JD et al., Ann NY Acad Sci. 2008 Apr;1127:116-20. FEBS Lett. 2006, Vol.580, pp.2717-2722. Furukawa M. et al., "Determining the optimal mating time of F344 rats by vaginal impedance method," Experimental Animal Technology, 22(2), 82-85, 1987.
[0011] The inventors of the present invention have further conducted clinical studies of bioelectrical impedance measurements in humans and additional experiments of bioelectrical impedance measurements in mouse models, and have obtained new findings regarding prediction of uterine implantation capacity and estimation of delivery time (or prediction of preterm birth). Therefore, an object of the present invention is to provide an apparatus and method for predicting the maternal uterine implantation capacity. Another object of the present invention is to provide an apparatus and method for estimating delivery time.
[0012] The present invention was completed based on the above findings and includes the following aspects: Namely, a first aspect of the present invention provides an apparatus for predicting the implantation capacity of a subject's uterus, comprising: an electrode inserted to a position in either the uterine cavity or the vaginal cavity of the subject, a measuring means for measuring local bioelectrical impedance at the position, and a predicting means for predicting the implantation capacity using the measured local bioelectrical impedance as an index.
[0013] Furthermore, in the device according to the first aspect of the present invention, it is preferable that the prediction means includes a comparison means for comparing the measurement value with at least one of a predetermined threshold value and a control value, which is a value of local bioelectrical impedance at a position in the uterine cavity or vaginal cavity previously measured in a fertile woman, and a determination means for determining that the implantation ability in the corresponding menstrual cycle is poor if the measurement value is higher than the corresponding threshold value or control value, and for determining that the implantation ability in the corresponding menstrual cycle is good if the measurement value is the same as or lower than the corresponding threshold value or control value.
[0014] Preferably, the device according to the first aspect of the present invention further comprises output means for outputting the predicted implantation ability.
[0015] A second aspect of the present invention provides a method comprising the steps of inserting an electrode to a position either in the uterine cavity or the vaginal cavity of the subject, measuring local bioelectrical impedance at said position, and predicting said implantation ability using the measured local bioelectrical impedance as an index.
[0016] A third aspect of the present invention provides an apparatus for estimating the time of delivery of a subject (or predicting the possibility of premature delivery), comprising: an electrode that is brought into contact with the mucosal epithelium at a position in either the uterine cavity or the vaginal cavity of the subject; a measuring means that measures the bioelectrical impedance generated between the electrode and the mucosal epithelium; and an estimating (or predicting) means that estimates the time of delivery of the subject (predicts the possibility of premature delivery) using the measured value of the bioelectrical impedance as an index.
[0017] In the device according to the third aspect of the present invention, it is preferable that the estimation (or prediction) means includes: a comparison means for comparing the measurement value with at least one of a predetermined threshold value and a control value, which is a value of local bioelectrical impedance at a position in the uterine cavity or the vaginal cavity previously measured in a fertile woman; and a determination means for determining that the subject's time of delivery is relatively early (or the possibility of premature birth is relatively high) if the measurement value is lower than the corresponding threshold value or control value, and for determining that the subject's time of delivery is normal or relatively late (or the possibility of premature birth is relatively low) if the measurement value is the same as or higher than the corresponding threshold value or control value.
[0018] Preferably, the device according to the third aspect of the present invention further comprises output means for outputting the estimated time of delivery.
[0019] A fourth aspect of the present invention provides a method comprising the steps of contacting an electrode with the mucosal epithelium at a location in either the uterine cavity or the vaginal cavity of a subject, measuring local bioelectrical impedance at said location, and estimating the time of delivery of said subject (or predicting the possibility of premature birth) using the measured value of said bioelectrical impedance as an index.
[0020] According to one aspect of the present invention, an apparatus and method for predicting the implantation capacity of a maternal uterus can be provided. Specifically, by prospectively assessing uterine implantation capacity, efficient infertility treatment can be provided. As a result, fetuses can be conceived earlier than currently possible, and the costs of infertility treatment required for conception can be reduced. Therefore, couples who have not previously been able to undergo infertility treatment for financial reasons can now receive treatment. This is expected to ultimately improve the birth rate and contribute to securing Japan's economic and social infrastructure, which is currently struggling with the declining birthrate. Furthermore, by increasing the success rate of infertility treatment, the number of ovarian stimulation and egg retrieval procedures, which are expensive and burdensome to the mother, can be reduced. Furthermore, by improving the pregnancy rate per embryo transfer, the number of transferred embryos can be limited to one, which is expected to eliminate iatrogenic multiple pregnancies resulting from infertility treatment, a current problem in perinatal medicine.
[0021] According to another aspect of the present invention, an apparatus and method for estimating the timing of delivery (or predicting the likelihood of preterm birth) can be provided. In other words, a predictive parameter for preterm birth has a high negative predictive rate. By using this in combination with known parameters, it becomes possible to select cases requiring aggressive medical intervention, and to provide the necessary treatment to those who need it.
[0022] 1 is a block diagram showing a schematic configuration of an apparatus 1 according to a first embodiment of the present invention. 2 is a block diagram showing a schematic configuration of an apparatus 101 according to a modified example of the first embodiment of the present invention. 3 is a schematic diagram of a measurement electrode 202 that can be used in a second embodiment of the present invention. 4 is a graph showing measurement results of bioelectrical impedance within the uterine cavity measured at three different times in Experimental Example 1. 5 is a diagram showing (A) a comparison result between two groups, one that ultimately achieved pregnancy and one that did not, for bioelectrical impedance values measured locally within the uterine cavity in Experimental Example 1, and (B) an ROC curve (Receiver Operating Characteristic curve) and an AUC curve (Area Under the ROC curve) regarding whether bioelectrical impedance values measured locally within the uterine cavity can predict whether pregnancy will not occur in this menstrual cycle. 8 is a diagram showing (A) the results of a comparison between mice in which premature birth was induced by administration of Mifepristone and control mice, and (B) the results of ROC analysis of vaginal local bioelectrical impedance measured in Experimental Example 2. (A) the results of a comparison between mice in which premature birth was induced by administration of LPS and control mice, and (B) the results of ROC analysis of vaginal local bioelectrical impedance measured in Experimental Example 2. (B) the results of a comparison between mice in which premature birth was induced by administration of Mifepristone and control mice, of vaginal local bioelectrical impedance measured using frequencies of 5 kHz, 10 kHz, 50 kHz, 125 kHz, or 250 kHz in Experimental Example 2-3. (C) the results of ROC analysis of the measurement results of FIG. 10 is a diagram showing the results of a comparison of vaginal local bioelectrical impedance measured using frequencies of 5 kHz, 10 kHz, 50 kHz, 125 kHz, or 250 kHz between mice in which premature birth was induced by administration of LPS and control mice in Experimental Example 2-4. 11 is a diagram showing the results of ROC analysis of the measurement results in Fig. 10. 12 is a diagram showing the relationship between successive frequencies and AUC for mice in which premature birth was induced by administration of LPS in Experimental Example 2-4.
[0023] Representative embodiments of the method and apparatus according to the present invention will be described in detail below with reference to the drawings, but these are merely examples of the present invention and the present invention is not limited to these. Note that the drawings are for conceptually explaining the present invention and therefore dimensions, ratios, or numbers may be exaggerated or simplified for ease of understanding.
[0024] 1. Embodiment 1 As one embodiment of the present invention, embodiment 1 will be described. Embodiment 1 relates to prediction of the implantation ability of the uterus.
[0025] (1) Method for Predicting Uterine Implantation Capacity The method for predicting uterine implantation capacity according to this embodiment uses bioelectrical impedance in the uterine cavity of a subject as an index. The subject here is assumed to be a woman who wishes to have a child, particularly a woman who is undergoing in vitro fertilization and embryo transfer treatment.
[0026] The bioelectrical impedance (AC electrical resistance value) within the uterine cavity can be measured by inserting at least two electrodes into the uterine cavity and contacting them with the endometrium, and applying an AC voltage of a predetermined frequency between the electrodes to pass an AC current. The current value of the current flowing between each electrode and the endometrium and the potential generated in the endometrium (the potential difference (voltage value) between the electrodes) are measured, and the bioelectrical impedance within the uterine cavity can be detected based on the current and voltage values. Platinum electrodes or tungsten electrodes are preferably used as the electrodes. Furthermore, the electrodes are preferably shaped (probe-shaped) so that they can be inserted into the uterine cavity. Regarding the electrode placement, either a two-terminal method in which two electrodes are placed within the uterine cavity or a four-terminal method in which four electrodes are placed within the uterine cavity may be used.
[0027] The prediction method according to this embodiment can be carried out by comparing the thus obtained intrauterine bioelectrical impedance values (these values are collectively referred to as "subject values") with intrauterine bioelectrical impedance values (these values are collectively referred to as "control values") obtained from a fertile woman (hereinafter referred to as a "control subject"). Here, "fertile woman" literally refers to a woman who is capable of becoming pregnant, and preferably refers to a woman who has a history of becoming pregnant.
[0028] If sexual intercourse coincides with ovulation during the menstrual cycle, the live birth rate per menstrual cycle is thought to be approximately 10-25%. This means that even fertile women (especially those with a history of pregnancy) do not conceive every cycle. In current infertility treatments, in vitro fertilization and embryo transfer (IVF) have become a common treatment, making it possible to identify problems with (i) ovulation and (ii) fertilization and conception. However, implantation failure is simply a pathological condition that refers to the failure to conceive despite the absence of problems in (i) and (ii) above. This is because there is currently no diagnostic method for implantation failure. There are currently no established criteria for determining whether uterine implantation capacity is normal. Until now, uterine implantation capacity has been predicted post hoc based on (1) blood progesterone levels, (2) ultrasound measurements of endometrial thickness, and (3) endometrial biopsy and the resulting pregnancy status. In infertility treatment patients, rather than irreversibly developing implantation failure, the situation is thought to change with each cycle. This means that many patients thought to be infertile due to implantation failure can be treated, or it is thought possible to develop an endometrial condition suitable for implantation. This is because it is not uncommon for patients to conceive naturally during the treatment hiatus. Therefore, it is necessary to prospectively evaluate the uterine implantation potential every menstrual cycle and provide treatment tailored to the situation.
[0029] Therefore, as a result of the above comparison, if the test value is higher than the corresponding control value, it can be determined that the implantation ability of the subject's uterus during that menstrual cycle is insufficient for embryo implantation, i.e., "poor implantation ability." On the other hand, if the test value is the same as or lower than the corresponding control value, it can be determined that the implantation ability of the subject's uterus during that menstrual cycle is sufficient for embryo implantation, i.e., "good implantation ability."
[0030] For example, if a woman undergoing in vitro fertilization and embryo transfer is diagnosed with "poor implantation capacity," the embryo transfer can be canceled and the embryos can be frozen or stored without using previously frozen embryos. The embryo transfer can then be postponed until the menstrual cycle in which "good implantation capacity" is determined, thereby avoiding unnecessary embryo transfers. On the other hand, if the woman is diagnosed with "good implantation capacity," the uterine implantation capacity during that menstrual cycle is deemed appropriate, and therefore an embryo transfer using a fresh embryo or a frozen embryo can be thawed and transferred. In this way, it is possible to provide efficient infertility treatment and reduce the financial and physical burden on patients.
[0031] Alternatively, the prediction method of this embodiment can be implemented by comparing the test value with a preset threshold value.
[0032] As a result of the above comparison, if the test value is higher than the corresponding threshold value, it can be determined that the implantation ability in the subject's uterus during that menstrual cycle is not sufficient for embryo implantation, i.e., "poor implantation ability." On the other hand, if the test value is the same as or lower than the corresponding threshold value, it can be determined that the implantation ability in the subject's uterus during that menstrual cycle is sufficient for embryo implantation, i.e., "good implantation ability."
[0033] (2) Apparatus for predicting uterine implantation ability and its operating method Fig. 1 is a block diagram showing the configuration of an apparatus 1 according to one embodiment of the present invention. The apparatus 1 is composed of a measurement electrode 2, an impedance measuring device 10, a control device 6, and an output device 7.
[0034] The measurement electrode 2 is formed in a needle shape (probe type) as a whole so that it can be inserted into the uterine cavity of a subject. In this embodiment, the measurement electrode 2 includes a body portion 20 and electrodes 21 and 22 arranged at a predetermined distance from the tip of the body portion 20. The tip of the body portion 20 is rounded to prevent damage to the uterine vagina of the subject. When the electrodes 21 and 22 are inserted into the uterine cavity and brought into contact with the endometrium, a current path is formed between the electrodes 21 and 22 and the endometrium. When an AC voltage is applied between the electrodes 21 and 22, a current corresponding to the bioelectrical impedance (endometrial impedance) between the electrodes 21 and 22 and the endometrium flows through the current path. Here, an AC voltage of 2.5-250 kHz can be used, but the usable frequency band is not limited to this.
[0035] The impedance measuring instrument 10 includes a power supply 3, an ammeter 4 that measures the current flowing through the current path, a voltmeter 9 that measures the potential difference (voltage value) between the electrodes 21 and 22, and impedance measuring means 5. The power supply 3, the ammeter 4, and the voltmeter 5 are electrically connected to the electrodes 21 and 22 via lead wires.
[0036] The power supply 3 is a power supply for applying an AC voltage of a predetermined frequency (for example, 2.5-250 kHz) between the electrodes 21 and 22, and a switching element 8 controls ON / OFF of the voltage application to the electrodes 21 and 22. The ON / OFF operation of the switching element 8 is controlled by the impedance measuring means 5.
[0037] The impedance measurement means 5 performs processes such as controlling the supply of current to the electrodes 21 and 22 and controlling the ammeter 4 and voltmeter 9. Upon receiving an operation signal from the subject, the impedance measurement means 5 controls the supply of current to the electrodes 21 and 22 by controlling the switching element 8 to turn on and off, and calculates bioelectrical impedance from the voltage value measured by the voltmeter 5 and the current value measured by the ammeter 4. Here, a known method can be used as a method for measuring bioelectrical impedance.
[0038] The control device 6 is a semiconductor integrated circuit that performs processing, including predicting the subject's uterine receptivity, using the bioelectrical impedance values measured by the impedance measuring device 10. The control device 6 can be configured as a microcomputer including a CPU, ROM, and RAM. The ROM stores bioelectrical impedance measurements (control values) from the uterine cavity of a fertile woman. The RAM temporarily stores the subject's endometrial impedance measured by the impedance measuring device 10. The CPU reads the subject's test value stored in the RAM and compares it with the control value for a fertile woman stored in the ROM. If the test value is higher than the corresponding control value, the subject's receptivity in that menstrual cycle is determined to be poor. On the other hand, if the test value is the same as or lower than the corresponding control value, the subject's receptivity in that menstrual cycle is determined to be good.
[0039] The output device 7 is composed of a display device such as a liquid crystal display, and displays the measured value (test value) of the endometrial impedance measured by the impedance measuring device 10, the assessment result of the subject's uterine implantation ability obtained by the control device 6, etc. Note that the output device 7 is not necessarily limited to a display device, and various types of devices such as a projector, printer, speaker, etc. can be used as long as they are capable of outputting the measured value (test value) of the intrauterine bioelectrical impedance measured by the impedance measuring device 10, the measurement result of the subject's uterine implantation ability obtained by the control device 6, etc. to the outside.
[0040] According to the device 1 of the present embodiment described above, the electrodes 21 and 22 are brought into contact with the inside of the uterine cavity of the subject to detect the potential generated in the subject's endometrium. The detected potential is used to calculate the subject's endometrial impedance, allowing for real-time evaluation of the subject's uterine implantation capacity. This evaluation makes it possible to prospectively evaluate the uterine implantation capacity for each menstrual cycle and to treat the resulting condition.
[0041] (3) Modifications of Embodiment 1 (3-1) Modification 1 In Embodiment 1, the uterine implantation ability of a subject in a certain menstrual cycle is measured by comparing the test value (measured value of bioelectrical impedance in the uterine cavity) with the measured value of bioelectrical impedance in the uterine cavity of a fertile woman (control value). In Modification 1, the test value may be compared with each of predetermined threshold values instead of or in addition to the control value.
[0042] (3-2) Modification 2 In the first embodiment, the bioelectrical impedance in the uterine cavity is measured by the two-terminal method, but the bioelectrical impedance may also be measured by the four-terminal method. Specifically, the measurement electrode 102 shown in Fig. 2 is formed in a needle shape (probe type) as a whole so that it can be inserted into the uterine cavity of the subject. The measurement electrode 102 includes a body portion 120 and electrodes 121 to 124 arranged at a predetermined interval at the tip of the body portion 120.
[0043] The electrodes 121 to 124 are each electrically connected by a lead wire to the impedance measuring instrument 110. Specifically, they are divided into two electrodes for passing current and two electrodes for measuring voltage, and the electrodes 121 and 124 at both ends are electrically connected to the ammeter 104, while the electrodes 122 and 123 are electrically connected to the voltmeter 109.
[0044] The impedance measurement means 105 performs processes such as controlling the supply of current to the electrodes 121 to 124 and controlling the ammeter 104 and voltmeter 109. Upon receiving an operation signal from the subject, the impedance measurement means 105 controls the ON / OFF of the switching element 108 to control the supply of current to the electrodes 121, 124, and causes a current to flow through a current path formed between the electrodes 121, 124 and the endometrium. Then, the bioelectrical impedance can be calculated from the current value measured by the ammeter 104 and the voltage value measured by the voltmeter 109.
[0045] 2. Embodiment 2 Another embodiment of the present invention will be described below as embodiment 2. Embodiment 2 relates to estimating the time of delivery or predicting the possibility of premature birth.
[0046] (1) Method for Estimating the Timing of Delivery The inventors have found that differences in timing of delivery from normal times are due to histological changes in the cervix, and the method for estimating timing of delivery according to this embodiment uses the bioelectrical impedance of the subject's vaginal cavity, i.e., vaginal mucosal impedance, as one indicator. It has previously been reported that the composition of mucus on the cervix and vaginal mucosal epithelium changes during the mechanism of delivery. However, the inventors focused on the increase in sulfate and sialic acid modifications of the glycocalyx and came to believe that it is possible to estimate the timing of delivery by measuring local bioelectrical impedance based on these material bases.
[0047] Specifically, the method for estimating the timing of delivery in this embodiment includes the step of (a) comparing a local bioelectrical impedance measurement value (test value) in the vaginal cavity measured in a subject with a vaginal mucosal impedance value (control value) previously measured in a fertile woman or a preset threshold. The vaginal mucosal impedance is measured by bringing electrodes into contact with the vaginal mucosal epithelium and measuring the voltage and current between the electrodes under an AC voltage of a predetermined frequency band.
[0048] This prediction method includes the step of (b) predicting that the time of delivery in the subject will be relatively early (or the likelihood of preterm birth will be relatively high) if the test value is lower than the corresponding control value or threshold, and determining that the time of delivery in the subject will be normal or relatively late (or the likelihood of preterm birth will be relatively low) if the test value is the same as or higher than the corresponding control value or threshold. The inventors believe that during the process of labor and preterm birth, changes in the expression of sulfated glycocalyx and / or sialylated glycocalyx (glycoproteins and polysaccharides that coat cell surfaces) in parts of the placenta and cervical epithelium are reflected in changes in measured local bioelectrical impedance. Therefore, the above-mentioned method can be used to estimate the time of delivery and predict the likelihood of preterm birth.
[0049] (2) Device for estimating the timing of delivery The device 1 described above can be used as a device for estimating the timing of delivery. However, the control value or threshold to be compared with the test value is changed as appropriate. The electrodes are inserted into the vagina. Therefore, as shown in Figure 3, a measuring electrode 202 including a substantially disk-shaped body portion 220 and electrodes 221-224 arranged at predetermined intervals on one side of the body portion 220 is preferably used.
[0050] Although one embodiment of the method and device for predicting uterine implantation ability and estimating the timing of delivery according to the present invention has been described above, the present invention is not limited to these embodiments. In embodiment 1, bioelectrical impedance within the uterine cavity was measured to predict uterine implantation ability, but instead of or in addition to this, bioelectrical impedance within the vaginal cavity may be measured and compared with a control value or threshold. Furthermore, in embodiment 2, bioelectrical impedance within the vaginal cavity was measured to estimate the timing of delivery, but instead of or in addition to this, bioelectrical impedance within the uterine cavity may be measured and compared with a control value or threshold.
[0051] The following experimental examples will be used to specifically explain the configuration and effects of the present invention. However, the present invention is not limited to these experimental examples. All of the following experimental examples were conducted with the approval of the Ethics Committee of the Graduate School of Medicine, Osaka University.
[0052] Experimental Example 1: Measurement of Bioelectrical Impedance in the Uterine Cavity of Humans. A body composition analyzer utilizing multi-frequency bioelectrical impedance analysis (Body Composition Analyzer MLT-550N manufactured by SK Medical Electronics Co., Ltd.) was fabricated by attaching a sensor-equipped intrauterine catheter (manufactured by TSS Healthcare Co., Ltd.) as an electrode. The electrodes of this device were inserted into the uterine cavity of a subject, and an AC voltage of 2.5-250 kHz and a maximum of 20 mV was generated between the electrodes to measure bioelectrical impedance. Measurement times were T1: before ovulation after the end of menstruation (e.g., days 9-10 after the onset of menstruation), T2: at the time of ovulation (e.g., the day before the start of progesterone administration in a hormone replacement cycle), and T3: immediately before embryo transfer. No adverse events such as bleeding, infection, or abdominal pain were observed. Furthermore, the pregnancy rate after measurement was 36.2%, suggesting that this measurement does not clearly inhibit pregnancy.
[0053] Figure 4 shows a comparison of the measurement results between the group that achieved pregnancy and the group that did not. Figure 5 shows the ROC (Receiver Operating Characteristic) analysis of the measurement results in Figure 4. The AUC (Area Under the ROC Curve) was 0.88, suggesting that the measurement values can be used to predict whether pregnancy will not occur in this menstrual cycle.
[0054] As shown in Figure 4, a significant difference was observed in the T1 phase under AC voltage of either frequency. This period corresponds to the time when the endometrium begins to thicken. Therefore, it can be seen that by measuring the bioelectrical impedance in the uterine cavity before ovulation after the end of menstruation (for example, on the 9th or 10th day after the onset of menstruation), it is possible to predict whether pregnancy will not occur during that menstrual cycle.
[0055] These results suggest that by measuring the local bioelectrical impedance value within the uterine cavity and using this value as an index, it is possible to prospectively predict the implantation capacity of the uterus and reflect this in treatment plans for each menstrual cycle.
[0056] Experimental Example 2: Measurement of local bioelectrical impedance in the vaginal cavity using a premature birth model mouse (1) Preparation of experimental animals (a) Premature birth model mouse: Premature birth model mice were prepared. The first premature birth model mouse was a mouse in which premature birth was induced by blocking progesterone through administration of mifepristone (RU-486). The second premature birth model mouse was a mouse in which premature birth was induced by local intrauterine infection through administration of lipopolysaccharide (LPS), a bacterial component. (b) Control mouse: A control mouse for the premature birth model mouse was also prepared according to the description in Non-Patent Document 2. (2) Measurement of vaginal mucosal impedance: Using the prepared premature birth model mouse and control mouse, the bioelectrical impedance of the vaginal mucosal epithelium was measured and compared. In this experimental example, a device was created in which a 4-electrode sensor was attached as an electrode to a body composition analyzer (body composition analyzer MLT-550N manufactured by SK Medical Electronics Co., Ltd.) that utilizes the multi-frequency bioelectrical impedance method, and bioelectrical impedance was measured.
[0057] [Experimental Example 2-1] In Experimental Example 2-1, a first preterm birth model mouse (progesterone-blocked preterm birth model) administered with mifepristone was used as a preterm birth model mouse, and local vaginal bioelectrical impedance was measured 15 hours after administration. Figure 6 (A) shows a comparison of local bioelectrical impedance measurements between two groups: a group that ultimately resulted in preterm birth (right side) and a group that did not result in preterm birth (left side). Figure 6 (B) shows the results of ROC analysis of the measurement results in (A). The AUC was 0.93.
[0058] [Experimental Example 2-2] In Experimental Example 2-2, a second preterm birth model mouse (infectious disease-induced preterm birth model) administered with LPS was used as a preterm birth model mouse. Here, local vaginal bioelectrical impedance was measured 10 hours after LPS administration. Figure 7(A) shows a comparison of the ratio of local bioelectrical impedance measurements between the group that ultimately achieved preterm birth (right side) and the group that did not achieve preterm birth (left side). Figure 7(B) shows the results of ROC analysis of the measurement results in (A). The AUC was 0.75.
[0059] 6 and 7, it was confirmed that the measured values of vaginal bioelectrical impedance in the preterm birth model mice were significantly lower than those in the control mice. Thus, it was confirmed that the measured values of vaginal bioelectrical impedance were significantly lower when preterm birth occurred. This suggests that the measured values of vaginal bioelectrical impedance can be used as a parameter for estimating the time of delivery (or preterm birth).
[0060] These results suggest that by measuring local vaginal bioelectrical impedance and using this value as an index, it is possible to estimate the timing of delivery (or predict the possibility of premature birth) and reflect this in treatment plans.
[0061] [Experimental Example 2-3] Next, in Experimental Example 2-3, first preterm birth model mice (progesterone-blocked preterm birth model) administered with mifepristone were prepared. Parturition occurred in all first preterm birth mice 16 to 20 hours after administration of mifepristone. Using these first preterm birth mice, vaginal local bioelectrical impedance was measured at 33 multiple frequencies 15 hours after administration of mifepristone, as described above, and measurements at five of these frequencies were examined. Figure 8 shows a comparison of local bioelectrical impedance measurements at frequencies of 5 kHz, 10 kHz, 50 kHz, 125 kHz, and 250 kHz between two groups: a group that ultimately resulted in preterm birth (right side) and a group that did not result in preterm birth (left side). Furthermore, Figure 9 shows the results of ROC analysis of the measurement results in Figure 8. In Experimental Example 2-3, the AUC was also close to 1.00 in relation to continuous frequencies (33 points).
[0062] [Experimental Example 2-4] Furthermore, in Experimental Example 2-4, a second preterm birth model mouse (infectious disease-induced preterm birth model) was prepared. Using the second preterm birth mouse, which underwent delivery within 24 hours after administration of 2 μg or 20 μg of LPS, local vaginal bioelectrical impedance was measured at 33 multiple frequencies, five of which were measured at 10 hours after LPS administration, in the same manner as described above. Figure 10 shows a comparison of local bioelectrical impedance measurements at frequencies of 5 kHz, 10 kHz, 50 kHz, 125 kHz, and 250 kHz between the group that ultimately resulted in preterm birth (right) and the group that did not result in preterm birth (left). Figure 11 also shows the results of ROC analysis of the measurement results in Figure 10. Additionally, Figure 12 shows a graph showing the relationship between successive frequencies and AUC in Experimental Example 2-4.
[0063] Figures 8 and 10 confirmed that the vaginal bioelectrical impedance measurements in the preterm birth model mice were significantly lower than those in the control mice. Thus, it was confirmed that the vaginal bioelectrical impedance measurements showed significantly lower values when preterm birth occurred. This also suggests that the vaginal bioelectrical impedance measurements can be used as a parameter for estimating the timing of delivery (or preterm birth). Furthermore, Figures 9 and 11 confirmed that the second preterm birth model mouse (infectious disease preterm birth model) showed significantly lower vaginal bioelectrical impedance measurements when preterm birth occurred than the first preterm birth model mouse (progesterone-blocked preterm birth model). These results suggest that measuring vaginal bioelectrical impedance using the second preterm birth model mouse (infectious disease preterm birth model) and using the measured value as an index can estimate the timing of delivery (or predict the possibility of preterm birth) and reflect this in treatment strategies.
[0064] Furthermore, Figure 11 shows that when a second preterm birth mouse model (infectious disease preterm birth model) was used and a high frequency range of 50 kHz to 250 kHz was used, the measured vaginal bioelectrical impedance showed significantly lower values when preterm birth occurred, i.e., frequency dependence was confirmed (50 kHz to 250 kHz is preferred). Figure 12 shows that when a high frequency of 100 kHz or higher or 125 kHz or higher was used, the AUC value became almost constant and a plateau was confirmed, confirming significant frequency dependence (100 kHz to 250 kHz or 125 kHz to 250 kHz is preferred).
[0065] In the above experimental example, the first group of mice in the preterm birth model administered mifepristone was analyzed at two doses: 0 μg or 250 μg. Meanwhile, the second group of mice in the preterm birth model induced by infection received LPS directly into the uterine cavity. As previously reported (Rinaldi et al. (2014) J Immunol 192: 2315-25), 100% of mice administered 20 μg achieved preterm birth within 24 hours of administration. To investigate whether preterm birth could be predicted by the measured parameters even under conditions where preterm birth was induced in some mice but not in others at a dose lower than the LPS dose required for 100% preterm birth, an additional group was administered 2 μg (1 / 10 the dose). The mice were divided into two groups: those that achieved preterm birth within 24 hours of administration and those that did not. Preterm birth was then predicted retrospectively based on the measured values 10 hours after administration.
[0066] Since most infertility cases are caused by a temporary imbalance, they are treatable conditions. Therefore, prospective diagnosis for each menstrual cycle and treatment tailored to the condition are effective. Therefore, real-time, prospective measurement of uterine implantation capacity can be reflected in infertility treatment. Specifically, if the measurement results indicate good uterine implantation capacity (sufficient uterine implantation readiness), embryo transfer using fresh or cryopreserved embryos is performed. On the other hand, if the uterine implantation capacity is determined to be poor (not yet ready for implantation), embryo transfer is not performed for that cycle, and embryos are cryopreserved instead, and embryo transfer is not performed for that cycle. By performing embryo transfer in cycles where uterine implantation capacity is determined to be suitable, highly efficient infertility treatment can be provided. In other words, by reducing unnecessary embryo transfers, the number of repeated ovarian hyperstimulation and egg retrieval procedures, which have been performed in the past, can also be reduced.
[0067] Furthermore, by measuring the bioelectrical impedance of the vaginal area after implantation and using this value as an index, it is possible to estimate the time of delivery (or predict the possibility of preterm birth). In other words, existing predictive parameters for preterm birth have a high negative predictive rate. By using this parameter in combination with known parameters, it becomes possible to select cases requiring aggressive medical intervention, and to provide the necessary treatment to those who need it.
[0068] 1,101 Device 2,102 Electrode 6,106 Control device 7,107 Output device 10,110 Impedance measuring device
Claims
1. A device for estimating the time of delivery of a subject, comprising: an electrode that is brought into contact with mucosal epithelium at a position in either the uterine cavity or the vaginal cavity of the subject; a measuring means that measures bioelectrical impedance generated between the electrode and the mucosal epithelium; and an estimation means that estimates the time of delivery of the subject using the measured value of the bioelectrical impedance as an index.
2. The device of claim 1, wherein the estimation means includes: a comparison means for comparing the measurement value with at least one of a predetermined threshold value and a control value which is a value of local bioelectrical impedance at a position in the uterine cavity or the vaginal cavity previously measured in a fertile woman; and a determination means for determining that the subject is in early labor if the measurement value is lower than the corresponding threshold value or control value.
3. The device according to claim 1, further comprising an output means for outputting the estimated time of delivery.
4. A method comprising the steps of: contacting an electrode with the mucosal epithelium at a location in either the uterine cavity or the vaginal cavity of the subject; measuring local bioelectrical impedance at said location; and estimating the time of delivery of the subject using the measured value of the bioelectrical impedance as an index.
5. An apparatus for predicting the implantation ability of a subject's uterus, comprising: an electrode that is inserted into either the uterine cavity or the vaginal cavity of the subject; a measuring means for measuring local bioelectrical impedance at said location; and a predicting means for predicting said implantation ability using the measured local bioelectrical impedance as an index.
6. The device described in claim 5, characterized in that the prediction means includes: a comparison means for comparing the measurement value with at least one of a predetermined threshold value and a control value which is a value of local bioelectrical impedance at a location in the uterine cavity or vaginal cavity previously measured in a fertile woman; and a determination means for determining that the implantation ability in the corresponding menstrual cycle is poor if the measurement value is higher than the corresponding threshold value or control value, and for determining that the implantation ability in the corresponding menstrual cycle is good if the measurement value is the same as or lower than the corresponding threshold value or control value.
7. The device according to claim 5, further comprising an output means for outputting the predicted implantation ability.
8. A method comprising the steps of: inserting an electrode into either the uterine cavity or the vaginal cavity of a subject; measuring local bioelectrical impedance at said location; and predicting said implantation ability using the measured local bioelectrical impedance value as an index.
Citation Information
Patent Citations
Devices, systems and methods for bioimpedance measurements of cervical tissue and methods for diagnosis and treatment of the human cervix
JP2006525099A
Apparatus and methods for determining force applied to the tip of a probe
US20190000388A1
Device and Method for Pre-Term Birth Risk Assessment
US20220296221A1
Endometrial receptivity measurement method and measurement device, and method for operation of the measurement device
WO2012070569A1
Vagina evaluation device and uterus evaluation deveices
WO2015146172A1
